GlassScriptPhysician profile
Lynda E Mbah
NPI 1669799060
$2,361.88
in general payments reported to CMS, 2019-2025
34 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $591 · 2020: $399 · 2021: $364 · 2022: $253 · 2023: $318 · 2024: $157 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $754.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $382.72 | 2019-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.84 | 2019-2023 | Jardiance |
| Amgen INC. | $232.90 | 2020-2025 | Repatha, Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $176.86 | 2019-2023 | Trintellix |
| Abbvie INC. | $157.47 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $133.96 | 2019-2025 | Airsupra, Farxiga |
| Merck Sharp & Dohme LLC | $124.96 | 2019-2022 | |
| Lilly USA, LLC | $109.93 | 2019-2024 | Jardiance, Zepbound, Emgality |
| Vivus LLC | $66.23 | 2022-2024 | Qsymia |
| Boston Scientific Corporation | $58.33 | 2025 | Wavewriter Alpha Prime 16 |
| Pfizer INC. | $57.73 | 2019-2023 | |
| Genentech USA, INC. | $49.75 | 2020-2021 | |
| Amarin Pharma, INC. | $47.95 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $45.73 | 2019-2020 | |
| Si-Bone, INC. | $35.55 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $35.50 | 2019-2021 | |
| Shire North American Group INC | $32.92 | 2019 | |
| Exact Sciences Corporation | $32.79 | 2024 | Cologuard Collection Kit |
| Bausch Health US, LLC | $32.61 | 2020 | |
| Glaxosmithkline, LLC. | $29.77 | 2019 | |
| Medtronic Minimed, INC. | $26.64 | 2019 | |
| Eisai INC. | $26.55 | 2019-2021 | |
| Corium, LLC | $22.86 | 2023 | Azstarys |
| Idorsia Pharmaceuticals US INC | $22.80 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.42 | 2019 | |
| Currax Pharmaceuticals LLC | $21.99 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $18.19 | 2019 | |
| Jazz Pharmaceuticals INC. | $17.33 | 2021 | |
| Optos, INC. | $16.84 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.45 | 2022 | |
| Allergan, INC. | $12.14 | 2020 | |
| Radius Health, INC. | $12.09 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.04 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $11.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynda Mbah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.